Daniel Martín Arsanios

Samuel Serrano

Bayron Espinel

Elias Quintero

María José Rincón

Alirio Bastidas Goyes


El déficit de hierro sin anemia se encuentra presente en diversas patologías de la práctica clínica; sin embargo, se conoce poco sobre la importancia, las complicaciones y los beneficios de su tratamiento. Este artículo describe la evidencia actual sobre distintas vías fisiopatológicas, abordaje y tratamiento de las principales patologías relacionadas con la ferropenia sin anemia. Para ello se realizó una búsqueda completa y actualizada de la literatura científica en Medline, OVID, Lilacs, SciELO y EMBASE utilizando una estrategia definida con términos MeSH y no MeSH, limitado a español e inglés.



deficiencia de hierro; anemia; hierro

1. Sohrabi F. Tip of the iceberg: Extra-haematological consequences of early iron deficiency. J Glob Health [Internet]. 2015;5(2):20304. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/26421147 %0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC4587592 %0Ahttp://www.jogh.org/pdfviewer.html?pdf=documents/forthcoming/jogh-05-020304.pdf
2. Baart AM, van Noord PAH, Vergouwe Y, Moons KGM, Swinkels DW, Wiegerinck ET, et al. High prevalence of subclinical iron deficiency in whole blood donors not deferred for low hemoglobin. Transfusion [Internet]. 2013 Aug 1 [citado 2017 Oct 28];53(8):1670-7. Disponible en: http://doi.wiley.com/10,1111/j.1537-2995,2012,03956.x
3. Brittenham GM. Disorders of iron homeostasis: Iron deficiency and overload. En Hematology: Basic Principles and Practice. 7th ed. Philadelphia: Elsevier; 2013. p. 437-49.
4. Bentley DP, Williams P. Serum ferritin concentration as an index of storage iron in rheumatoid arthritis. J Clin Pathol [Internet]. 1974 Oct [citado 2017 Oct 25];27(10):786-8. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/4426972
5. Tessitore N, Solero GP, Lippi G, Bassi A, Faccini GB, Bedogna V, et al. The role of iron status markers in predicting response to intravenous iron in haemodialysis patients on maintenance erythropoietin. Nephrol Dial Transplant [Internet]. 2001 Jul [citado 2017 Oct 25];16(7):1416-23. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/11427634
6. Clénin GE. The treatment of iron deficiency without anaemia (in otherwise healthy persons). Swiss Med Wkly [Internet]. 2017 Jun 14 [citado 2017 Oct 25];147(2324):w14434. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/28634965
7. Wang W, Knovich MA, Coffman LG, Torti FM, Torti S V. Serum ferritin: Past, present and future. [citado 2017 Oct 25]. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2893236/pdf/nihms190912.pdf
8. Lopez A, Cacoub P, Macdougall IC, Peyrin-Biroulet L. Iron deficiency anaemia. Lancet. 2016;387(10021):907-16.
9. Mast AE, Blinder MA, Lu Q, Flax S, Dietzen DJ. Clinical utility of the reticulocyte hemoglobin content in the diagnosis of iron deficiency. Blood [Internet]. 2002 Feb 15 [citado 2017 Oct 28];99(4):1489-91. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/11830506
10. Urrechaga E, Borque L, Escanero JF. Clinical value of hypochromia markers in the detection of latent iron deficiency in nonanemic premenopausal women. J Clin Lab Anal [Internet]. 2016 Sep [citado 2017 Oct 28];30(5):623-7. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/26899023
11. Malczewska-Lenczowska J, Orysiak J, Szczepańska B, Turowski D, Burkhard-Jagodzińska K, Gajewski J. Reticulocyte and erythrocyte hypochromia markers in detection of iron deficiency in adolescent female athletes. Biol Sport. 2017;34(2):111-8.
12. Witte KKA, Desilva R, Chattopadhyay S, Ghosh J, Cleland JGF, Clark AL. Are hematinic deficiencies the cause of anemia in chronic heart failure? Am Heart J. 2004;147(5):924-30.
13. van Veldhuisen DJ, Anker SD, Ponikowski P, Macdougall IC. Anemia and iron deficiency in heart failure: Mechanisms and therapeutic approaches. Nat Rev Cardiol [Internet]. 2011;8(9):485-93. Disponible en: http://www.nature.com/doifinder/10,1038/nrcardio.2011,77
14. de Silva R, Rigby AS, Witte KKA, Nikitin NP, Tin L, Goode K, et al. Anemia, renal dysfunction, and their interaction in patients with chronic heart failure. Am J Cardiol [Internet]. 2006 Aug 1 [citado 2017 Oct 30];98(3):391-8. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/16860030
15. Jankowska EA, Rozentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska B, et al. Iron deficiency: An ominous sign in patients with systolic chronic heart failure. Eur Heart J [Internet]. 2010 Aug 1 [citado 2017 Oct 30];31(15):1872-80. Disponible en: https://academic.oup.com/eurheartj/article-lookup/doi/10,1093/eurheartj/ehq158
16. Grammer TB, Kleber ME, Silbernagel G, Pilz S, Scharnagl H, Tomaschitz A, et al. Hemoglobin, iron metabolism and angiographic coronary artery disease (The Ludwigshafen Risk and Cardiovascular Health Study). Atherosclerosis [Internet]. 2014 Oct [citado 2017 Oct 30];236(2):292-300. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/25112800
17. Meroño O, Cladellas M, Ribas-Barquet N, Recasens L, Bazán V, Comín-Colet J. Iron deficiency in patients with acute coronary syndrome: Prevalence and predisposing factors. Rev Española Cardiol (English Ed [Internet]. 2016 Jun 1 [citado 2017 Oct 30];69(6):615-7. Disponible en: http://linkinghub.elsevier.com/retrieve/pii/S188558571630010X
18. Huang C-H, Chang C-C, Kuo C-L, Huang C-S, Chiu T-W, Lin C-S, et al. Serum iron concentration, but not hemoglobin, correlates with TIMI risk score and 6-month left ventricular performance after primary angioplasty for acute myocardial infarction. En Guo Y, editor. PLoS One [Internet]. 2014 Aug 6 [citado 2017 Oct 30];9(8):e104495. Disponible en: http://dx.plos.org/10,1371/journal.pone.0104495
19. Jankowska EA, Wojtas K, Kasztura M, Mazur G, Butrym A, Kalicinska E, et al. Bone marrow iron depletion is common in patients with coronary artery disease. Int J Cardiol [Internet]. 2015 Mar 1 [citado 2017 Oct 30];182:517-22. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/25661858
20. Rangel I, Gonçalves A, De Sousa C, Leite S, Campelo M, Martins E, et al. Iron Deficiency status irrespective of anemia: A predictor of unfavorable outcome in chronic heart failure patients. Cardiology [Internet]. 2014 [citado 2017 Oct 31];128:320-6. Disponible en: https://www.karger.com/Article/Pdf/358377
21. Anand I. Iron deficiency in heart failure. Cardiol [Internet]. 2014;128(4):317-9. Disponible en: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed12&AN=2014459475 %5Cnhttp://sfx.scholarsportal.info/uhn?sid=OVID:embase&id=pmid:&id=doi:10,1159/000361040&issn=0008-6312&isbn=&volume=128&issue=4&spage=317&pages=317-319&date=2014&tit
22. Nanas JN, Matsouka C, Karageorgopoulos D, Leonti A, Tsolakis E, Drakos SG, et al. Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol [Internet]. 2006 Dec [citado 2017 Oct 31];48(12):2485-9. Disponible en: http://linkinghub.elsevier.com/retrieve/pii/S0735109706023485
23. Weiss G, Goodnough LT. Anemia of Chronic Disease. N Engl J Med [Internet]. 2005 Mar 10 [citado 2017 Oct 31];352(10):1011-23. Disponible en: http://www.nejm.org/doi/abs/10,1056/NEJMra041809
24. Naito Y, Tsujino T, Fujimori Y, Sawada H, Akahori H, Hirotani S, et al. Impaired expression of duodenal iron transporters in Dahl salt-sensitive heart failure rats. J Hypertens [Internet]. 2011 Apr 1 [citado 2017 Oct 31];29(4):741-8. Disponible en: https://insights.ovid.com/pubmed?pmid=21191310
25. Silverberg DS, Wexler D, Blum M, Keren G, Sheps D, Leibovitch E, et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol [Internet]. 2000 [citado 2017 Nov 1];35:1737-44. Disponible en: https://ac.els-cdn.com/S0735109700006136/1-s2,0-S0735109700006136-main.pdf?_tid=bd148f96-bf50-11e7-9717-00000aacb35f&acdnat=1509574096_de429c2657d8aecdee7c0b42205fd43f
26. Silverberg DS, Wexler D, Sheps D, Blum M, Keren G, Baruch R, et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol [Internet]. 2001 Jun 1 [citado 2017 Nov 1];37(7):1775-80. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/11401110
27. Palazzuoli A, Silverberg D, Iovine F, Capobianco S, Giannotti G, Calabrò A, et al. Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia. Am Heart J [Internet]. 2006 Dec [citado 2017 Nov 1];152(6):1096.e9-1096.e15. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/17161060
28. Mancini DM, Katz SD, Lang CC, LaManca J, Hudaihed A, Androne A-S. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation [Internet]. 2003 Jan 21 [citado 2017 Nov 1];107(2):294-9. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/12538431
29. Ponikowski P, Anker SD, Szachniewicz J, Okonko D, Ledwidge M, Zymlinski R, et al. Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure. J Am Coll Cardiol [Internet]. 2007 Feb 20 [citado 2017 Nov 1];49(7):753-62. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/17306703
30. Ghali JK, Anand IS, Abraham WT, Fonarow GC, Greenberg B, Krum H, et al. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation [Internet]. 2008 Jan 29 [citado 2017 Nov 1];117(4):526-35. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/18195176
31. van Veldhuisen DJ, Dickstein K, Cohen-Solal A, Lok DJA, Wasserman SM, Baker N, et al. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. Eur Heart J [Internet]. 2007 Aug 2 [citado 2017 Nov 1];28(18):2208-16. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/17681958
32. Bolger AP, Bartlett FR, Penston hierro sérico, O’Leary J, Pollock N, Kaprielian R, et al. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J Am Coll Cardiol [Internet]. 2006 Sep 19 [citado 2017 Nov 1];48(6):1225-7. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/16979010
33. Okonko D, Grzeslo A, Witkowski T, Mandal A, Slater R, Roughton M, et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency: FERRIC-HF: A randomized, controlled, observer-blinded trial. J Am Coll Cardiol [Internet]. 2008 Jan 15 [citado 2017 Nov 1];51(2):103-12. Disponible en: http://www.sciencedirect.com/science/article/pii/S0735109707033633
34. van Veldhuisen DJ, Ponikowski P, van der Meer P, Metra M, Böhm M, Doletsky A, et al. Effect of Ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation [Internet]. 2017 Oct 10 [citado 2017 Nov 2];136(15):1374-83. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/28701470
35. Lewis GD, Malhotra R, Hernandez AF, McNulty SE, Smith A, Felker GM, et al. Effect of Oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency. JAMA [Internet]. 2017 May 16 [citado 2017 Nov 2];317(19):1958. Disponible en: http://jama.jamanetwork.com/article.aspx?doi=10,1001/jama.2017,5427
36. Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, et al. Global Strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. Gold executive summary. Am J Respir Crit Care Med [Internet]. 2017 Mar 1 [citado 2017 Nov 4];195(5):557-82. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/28128970
37. Barberan-García A, Rodríguez DA, Blanco I, Gea J, Torralba Y, Arbillaga-Etxarri A, et al. Non-anaemic iron deficiency impairs response to pulmonary rehabilitation in COPD. Respirology. 2015;20(7):1089-95.
38. Robalo Nunes A, Tátá M. The impact of anaemia and iron deficiency in chronic obstructive pulmonary disease: A clinical overview. Rev Port Pneumol (English Ed [Internet]. 2017 May [citado 2017 Nov 2];23(3):146-55. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/28233650
39. Silverberg DS, Mor R, Weu MT, Schwartz D, Schwartz IF, Chernin G. Anemia and iron deficiency in COPD patients: Prevalence and the effects of correction of the anemia with erythropoiesis stimulating agents and intravenous iron. BMC Pulm Med [Internet]. 2014 Dec 24 [citado 2017 Nov 2];14(1):24. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/24564844
40. McKeever TM, Lewis SA, Smit HA, Burney P, Cassano PA, Britton J. A multivariate analysis of serum nutrient levels and lung function. Respir Res [Internet]. 2008 Dec 29 [citado 2017 Nov 5];9(1):67. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/18823528
41. Nguyen N-B, Callaghan KD, Ghio AJ, Haile DJ, Yang F. Hepcidin expression and iron transport in alveolar macrophages. Am J Physiol Lung Cell Mol Physiol [Internet]. 2006 Sep 1 [citado 2017 Nov 6];291(3):L417-25. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/16648237
42. González Alayón C, Pedrajas Crespo C, Marín Pedrosa S, Benítez JM, Iglesias Flores E, Salgueiro Rodríguez I, et al. Prevalencia de déficit de hierro sin anemia en la enfermedad inflamatoria intestinal y su impacto en la calidad de vida. Gastroenterol Hepatol [Internet]. 2017 Sep [citado 2017 Nov 7]; Disponible en: http://linkinghub.elsevier.com/retrieve/pii/S0210570517301899
43. Bou-Fakhredin R, Halawi R, Roumi J, Taher A. Insights into the diagnosis and management of iron deficiency in inflammatory bowel disease. Expert Rev Hematol [Internet]. 2017;10(9):801-8. Disponible en: http://dx.doi.org/10,1080/17474086,2017,1355233
44. Goddard AF, James MW, McIntyre AS, Scott BB, British Society of gastroenterology. guidelines for the management of iron deficiency anaemia. Gut [Internet]. 2011 Oct 1 [citado 2017 Nov 7];60(10):1309-16. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/21561874
45. Wilson A, Reyes E, Ofman J. Prevalence and outcomes of anemia in inflammatory bowel disease: a systematic review of the literature. Am J Med [Internet]. 2004 Apr 5 [citado 2017 Nov 7];116(7):44-9. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/15050885
46. Stein J, Connor S, Virgin G, Ong DEH, Pereyra L. Anemia and iron deficiency in gastrointestinal and liver conditions. World J Gastroenterol [Internet]. 2016 Sep 21 [citado 2017 Nov 7];22(35):7908-25. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/27672287
47. Stein J, Connor S, Virgin G, Ong DEH, Pereyra L. Anemia and iron deficiency in gastrointestinal and liver conditions. World J Gastroenterol. 2016;22(35):7908-25.
48. García Herce JA, Muñoz Gómez M. Hepcidina: una molécula clave para explicar la fisiopatología de la anemia. Gastroenterol y Hepatol Contin [Internet]. 2008 Jun [citado 2017 Nov 7];7(3):119-23. Disponible en: http://linkinghub.elsevier.com/retrieve/pii/S1578155008730018
49. Carlson ES, Tkac I, Magid R, O’Connor MB, Andrews NC, Schallert T, et al. Iron is essential for neuron development and memory function in mouse hippocampus. J Nutr [Internet]. 2009 Apr [citado 2017 Nov 7];139(4):672-9. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/19211831
50. Lozoff B, Georgieff MK. Iron deficiency and brain development. Semin Pediatr Neurol [Internet]. 2006 Sep [citado 2017 Nov 7];13(3):158-65. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/17101454
51. Todorich B, Pasquini JM, García CI, Páez PM, Connor JR. Oligodendrocytes and myelination: The role of iron. Glia [Internet]. 2009 Apr 1 [citado 2017 Nov 7];57(5):467-78. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/18837051
52. Bastian TW, von Hohenberg WC, Mickelson DJ, Lanier LM, Georgieff MK. Iron deficiency impairs developing hippocampal neuron gene expression, energy metabolism, and dendrite complexity. Dev Neurosci [Internet]. 2016 [citado 2017 Nov 7];38(4):264-76. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/27669335
53. Benes H, Walters AS, Allen RP, Hening WA, Kohnen R. Definition of restless legs syndrome, how to diagnose it, and how to differentiate it from RLS mimics. Mov Disord [Internet]. 2007 Jan 1 [citado 2017 Nov 7];22(S18):S401-8. Disponible en: http://doi.wiley.com/10,1002/mds.21604
54. Llaneza-González MA, Abella-Corral J, Aldrey-Vázquez JM, Aneiros-Díaz A, Macías-Arribi M, Santos-García D. Restless legs syndrome. Rev Neurol [Internet]. 2009 Jan 23 [citado 2017 Nov 7];48 Suppl 1:S33-6. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/19222013
55. O’Keeffe ST, Gavin K, Lavan JN. Iron status and restless legs syndrome in the elderly. Age Ageing [Internet]. 1994 May [citado 2017 Nov 7];23(3):200-3. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/8085504
56. Zobeiri M, Shokoohi A. Restless leg syndrome in diabetics compared with normal controls. Sleep Disord [Internet]. 2014 [citado 2017 Nov 7];2014:871751. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/24895540
57. Rizzo G, Manners D, Testa C, Tonon C, Vetrugno R, Marconi S, et al. Low brain iron content in idiopathic restless legs syndrome patients detected by phase imaging. Mov Disord [Internet]. 2013 Nov [citado 2017 Nov 7];28(13):1886-90. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/23780623
58. Connor JR, Wang X-S, Allen RP, Beard JL, Wiesinger JA, Felt BT, et al. Altered dopaminergic profile in the putamen and substantia nigra in restless leg syndrome. Brain [Internet]. 2009 Sep 1 [citado 2017 Nov 7];132(9):2403-12. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/19467991
59. Earley CJ, Connor JR, Beard JL, Malecki EA, Epstein DK, Allen RP. Abnormalities in CSF concentrations of ferritin and transferrin in restless legs syndrome. Neurology [Internet]. 2000 Apr 25 [citado 2017 Nov 7];54(8):1698-700. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/10762522
60. Connor JR, Ponnuru P, Lee B-Y, Podskalny GD, Alam S, Allen RP, et al. Postmortem and imaging based analyses reveal CNS decreased myelination in restless legs syndrome. Sleep Med [Internet]. 2011 Jun [citado 2017 Nov 7];12(6):614-9. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/21570342
61. Wang J, O’Reilly B, Venkataraman R, Mysliwiec V, Mysliwiec A. Efficacy of oral iron in patients with restless legs syndrome and a low-normal ferritin: A randomized, double-blind, placebo-controlled study. Sleep Med [Internet]. 2009 Oct [citado 2017 Nov 7];10(9):973-5. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/19230757
62. Sloand JA, Shelly MA, Feigin A, Bernstein P, Monk RD. A double-blind, placebo-controlled trial of intravenous iron dextran therapy in patients with ESRD and restless legs syndrome. Am J Kidney Dis [Internet]. 2004 Apr [citado 2017 Nov 7];43(4):663-70. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/15042543
63. Allen RP, Adler CH, Du W, Butcher A, Bregman DB, Earley CJ. Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: A multi-centred, placebo-controlled preliminary clinical trial. Sleep Med [Internet]. 2011 Oct [citado 2017 Nov 7];12(9):906-13. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/21978726
64. Cho YW, Allen RP, Earley CJ. Clinical efficacy of ferric carboxymaltose treatment in patients with restless legs syndrome. Sleep Med [Internet]. 2016 Sep [citado 2017 Nov 7];25:16-23. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/27823710
65. Trotti LM, Bhadriraju S, Becker LA. Iron for restless legs syndrome. En: Trotti LM, editor. Cochrane database of systematic reviews [Internet]. Chichester, UK: John Wiley & Sons; 2012 [citado 2017 Nov 7]. p. CD007834. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/22592724
66. Bruner AB, Joffe A, Duggan AK, Casella JF, Brandt J. Randomised study of cognitive effects of iron supplementation in non-anaemic iron-deficient adolescent girls. Lancet [Internet]. 1996 Oct 12 [citado 2017 Nov 7];348(9033):992-6. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/8855856
67. Ji X, Cui N, Liu J. Neurocognitive function is associated with serum iron status in early adolescents. Biol Res Nurs [Internet]. 2017 May 15 [citado 2017 Nov 7];19(3):269-77. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/28196427
68. Radlowski EC, Johnson RW. Perinatal iron deficiency and neurocognitive development. Front Hum Neurosci [Internet]. 2013 Sep 23 [citado 2017 Nov 7];7:585. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/24065908
69. Falkingham M, Abdelhamid A, Curtis P, Fairweather-Tait S, Dye L, Hooper L. The effects of oral iron supplementation on cognition in older children and adults: A systematic review and meta-analysis. Nutr J [Internet]. 2010 Jan 25 [citado 2017 Nov 7];9:4. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/20100340
70. Baumgartner J, Smuts CM, Malan L, Kvalsvig J, van Stuijvenberg ME, Hurrell RF, et al. Effects of iron and n-3 fatty acid supplementation, alone and in combination, on cognition in school children: a randomized, double-blind, placebo-controlled intervention in South Africa. Am J Clin Nutr [Internet]. 2012 Dec 1 [citado 2017 Nov 7];96(6):1327-38. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/23097272
71. Murray-Kolb LE, Beard JL. Iron treatment normalizes cognitive functioning in young women. Am J Clin Nutr [Internet]. 2007 Mar [citado 2017 Nov 7];85(3):778-87. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/17344500
72. Belaidi AA, Bush AI. Iron neurochemistry in Alzheimer’s disease and Parkinson’s disease: Targets for therapeutics. J Neurochem [Internet]. 2016 Oct [citado 2017 Nov 7];139:179-97. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/26545340
73. Carlson ES, Magid R, Petryk A, Georgieff MK. Iron deficiency alters expression of genes implicated in Alzheimer disease pathogenesis. Brain Res [Internet]. 2008 Oct 27 [citado 2017 Nov 7];1237:75-83. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/18723004
74. Yavuz BB, Cankurtaran M, Haznedaroglu IC, Halil M, Ulger Z, Altun B, et al. Iron deficiency can cause cognitive impairment in geriatric patients. J Nutr Health Aging [Internet]. 2012 Mar [citado 2017 Nov 7];16(3):220-4. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/22456776
75. Fishbane S, Pollack S, Feldman HI, Joffe MM. Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988-2004. Clin J Am Soc Nephrol [Internet]. 2009 Jan 1 [citado 2017 Nov 20];4(1):57-61. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/18987297
76. Martínez-Castelao A, Górriz JL, Portolés JM, De Alvaro F, Cases A, Luño J, et al. Baseline characteristics of patients with chronic kidney disease stage 3 and stage 4 in spain: the MERENA observational cohort study. BMC Nephrol [Internet]. 2011 Dec 5 [citado 2017 Nov 20];12(1):53. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/21970625
77. Ma JZ, Ebben J, Xia H, Collins a J. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol. 1999;10(3):610-9.
78. Luo J, Jensen DE, Maroni BJ, Brunelli SM. Spectrum and burden of erythropoiesis-stimulating agent hyporesponsiveness among contemporary hemodialysis patients. Am J Kidney Dis [Internet]. 2016 Nov [citado 2017 Nov 20];68(5):763-71. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/27528373
79. Babitt JL. Mechanisms of anemia in CKD. Med Clin North Am. 2012;40(3):857-70.
80. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest [Internet]. 2004 May 1 [citado 2017 Nov 20];113(9):1271-6. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/15124018
81. Babitt JL, Lin HY. Molecular mechanisms of hepcidin regulation: Implications for the anemia of CKD. Am J Kidney Dis [Internet]. 2010 Apr [citado 2017 Nov 20];55(4):726-41. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/20189278
82. Tessitore N, Girelli D, Campostrini N, Bedogna V, Pietro Solero G, Castagna A, et al. Hepcidin is not useful as a biomarker for iron needs in haemodialysis patients on maintenance erythropoiesis-stimulating agents. Nephrol Dial Transplant. 2010;25(12):3996-4002.
83. Thomas DW, Hinchliffe RF, Briggs C, Macdougall IC, Littlewood T, Cavill I, et al. Guideline for the laboratory diagnosis of functional iron deficiency. Br J Haematol [Internet]. 2013 Jun [citado 2017 Nov 20];161(5):639-48. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/23573815
84. Kalantar-Zadeh K, Kalantar-Zadeh K, Lee GH. The fascinating but deceptive ferritin: to measure it or not to measure it in chronic kidney disease? Clin J Am Soc Nephrol [Internet]. 2006 Sep 1 [citado 2017 Dec 24];1 Suppl 1(Supplement 1):S9-18. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/17699375
85. Rambod M, Kovesdy CP, Kalantar-Zadeh K. Combined high serum ferritin and low iron saturation in hemodialysis patients: The role of inflammation. Clin J Am Soc Nephrol [Internet]. 2008 Nov 1 [citado 2017 Nov 20];3(6):1691-701. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/18922994
86. Chapter 1: Diagnosis and evaluation of anemia in CKD. Kidney Int Suppl [Internet]. 2012 Aug [citado 2017 Nov 20];2(4):288-91. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/25018948
87. Vaziri ND. Safety issues in iron treatment in CKD. Semin Nephrol [Internet]. 2016 Mar [citado 2017 Nov 20];36(2):112-8. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/27236132
88. Stoves J, Inglis H, Newstead CG. A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin. Nephrol Dial Transplant. 2001;16(5):967-74.
89. Shepshelovich D, Rozen-Zvi B, Avni T, Gafter U, Gafter-Gvili A. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: An updated systematic review and meta-analysis. Am J Kidney Dis [Internet]. 2016 Nov [citado 2017 Nov 20];68(5):677-90. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/27321965
90. Tomer A, Amir B, Alon G, Hefziba G, Leonard L, Anat GG. The safety of intravenous iron preparations: Systematic review and meta-analysis. Mayo Clin Proc. 2015;90(1):12-23.
91. Stancu S, Stanciu A, Zugravu A, Bârsan L, Dumitru D, Lipan M, et al. Bone marrow iron, iron indices, and the response to intravenous iron in patients with non-dialysis-dependent CKD. Am J Kidney Dis [Internet]. 2010 Apr [citado 2017 Nov 20];55(4):639-47. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/20079959
92. Sanai T, Ono T, Fukumitsu T. Beneficial effects of oral iron in Japanese patients on hemodialysis. Intern Med [Internet]. 2017;56(18):2395-9. Disponible en: https://www.jstage.jst.go.jp/article/internalmedicine/56/18/56_8520-16/_article
Cómo citar
Martín Arsanios, D., Serrano, S., Espinel, B., Quintero, E., Rincón, M., & Bastidas Goyes, A. (2018). Ferropenia sin anemia, más que un hallazgo de laboratorio. Universitas Medica, 59(4), 1-22. https://doi.org/10.11144/Javeriana.umed59-4.ferr
Artículos de revisión
Artículos más leídos del mismo autor/a